{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:55:50Z","timestamp":1792727750709,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00991-0","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:03:46Z","timestamp":1729659826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1547-5159","authenticated-orcid":false,"given":"Jiaxing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupeng","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"991_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12250-016-3899-x","volume":"32","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Hantavirus infection: a global zoonotic challenge. Virol. Sin. 32, 32\u201343 (2017).","journal-title":"Virol. Sin."},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1473-3099(23)00128-7","volume":"23","author":"PA Vial","year":"2023","unstructured":"Vial, P. A. et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect. Dis. 23, e371\u2013e382 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"991_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1473-3099(03)00774-6","volume":"3","author":"O Vapalahti","year":"2003","unstructured":"Vapalahti, O. et al. Hantavirus infections in Europe. Lancet Infect. Dis. 3, 653\u2013661 (2003).","journal-title":"Lancet Infect. Dis."},{"key":"991_CR4","first-page":"1","volume":"6","author":"H Jiang","year":"2016","unstructured":"Jiang, H., Du, H., Wang, L. M., Wang, P. Z. & Bai, X. F. Hemorrhagic fever with renal syndrome: pathogenesis and clinical picture. Front. Cell. Infect. Microbiol. 6, 1 (2016).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"991_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrmicro3066","volume":"11","author":"A Vaheri","year":"2013","unstructured":"Vaheri, A. et al. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol. 11, 539\u2013550 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"991_CR6","first-page":"472","volume":"112","author":"G Song","year":"1999","unstructured":"Song, G. Epidemiological progresses of hemorrhagic fever with renal syndrome in China. Chin. Med. J. 112, 472\u2013477 (1999).","journal-title":"Chin. Med. J."},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/1469-0691.12291","volume":"21s","author":"T Av\u0161i\u010d-\u017dupanc","year":"2019","unstructured":"Av\u0161i\u010d-\u017dupanc, T., Saksida, A. & Korva, M. Hantavirus infections. Clin. Microbiol. Infect. 21s, e6\u2013e16 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/imm.13322","volume":"163","author":"F Saavedra","year":"2021","unstructured":"Saavedra, F. et al. Immune response during hantavirus diseases: implications for immunotherapies and vaccine design. Immunology 163, 262\u2013277 (2021).","journal-title":"Immunology"},{"key":"991_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000067925","volume":"45","author":"HW Cho","year":"2002","unstructured":"Cho, H. W., Howard, C. R. & Lee, H. W. Review of an inactivated vaccine against hantaviruses. Intervirology 45, 328\u2013333 (2002).","journal-title":"Intervirology"},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/1440-1681.13403","volume":"48","author":"N Munir","year":"2021","unstructured":"Munir, N. et al. Hantavirus diseases pathophysiology, their diagnostic strategies and therapeutic approaches: a review. Clin. Exp. Pharmacol. Physiol. 48, 20\u201334 (2021).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"991_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/(SICI)1096-9071(199608)49:4<333::AID-JMV13>3.0.CO;2-B","volume":"49","author":"Q Lu","year":"1996","unstructured":"Lu, Q., Zhu, Z. & Weng, J. Immune responses to inactivated vaccine in people naturally infected with hantaviruses. J. Med. Virol. 49, 333\u2013335 (1996).","journal-title":"J. Med. Virol."},{"key":"991_CR12","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3389\/fmicb.2019.02989","volume":"10","author":"R Liu","year":"2019","unstructured":"Liu, R. et al. Vaccines and therapeutics against hantaviruses. Front. Microbiol. 10, 2989 (2019).","journal-title":"Front. Microbiol."},{"key":"991_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/nbt1261","volume":"24","author":"JB Ulmer","year":"2006","unstructured":"Ulmer, J. B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377\u20131383 (2006).","journal-title":"Nat. Biotechnol."},{"key":"991_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1469-0691.2009.02848.x","volume":"15","author":"B Klempa","year":"2009","unstructured":"Klempa, B. Hantaviruses and climate change. Clin. Microbiol. Infect. 15, 518\u2013523 (2009).","journal-title":"Clin. Microbiol. Infect."},{"key":"991_CR15","doi-asserted-by":"publisher","first-page":"e0006901","DOI":"10.1371\/journal.pntd.0006901","volume":"13","author":"H Tian","year":"2019","unstructured":"Tian, H. & Stenseth, N. C. The ecological dynamics of hantavirus diseases: from environmental variability to disease prevention largely based on data from China. PLoS Negl. Trop. Dis. 13, e0006901 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"991_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal. Transduct. Target Ther. 7, 94 (2022).","journal-title":"Signal. Transduct. Target Ther."},{"key":"991_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"991_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.ymthe.2022.01.013","volume":"30","author":"A Sankaradoss","year":"2022","unstructured":"Sankaradoss, A. et al. Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences. Mol. Ther. 30, 2058\u20132077 (2022).","journal-title":"Mol. Ther."},{"key":"991_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"991_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00629-7","volume":"8","author":"LG Medina-Mag\u00fces","year":"2023","unstructured":"Medina-Mag\u00fces, L. G. et al. Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models. npj vaccines 8, 31 (2023).","journal-title":"npj vaccines"},{"key":"991_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511\u20131520 (2017).","journal-title":"Lancet"},{"key":"991_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"991_CR23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210\u20131216 (2012).","journal-title":"Nat. Biotechnol."},{"key":"991_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/erv.11.17","volume":"10","author":"D Christensen","year":"2011","unstructured":"Christensen, D., Korsholm, K. S., Andersen, P. & Agger, E. M. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 10, 513\u2013521 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"991_CR25","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1128\/JVI.00057-10","volume":"84","author":"JT Huiskonen","year":"2010","unstructured":"Huiskonen, J. T. et al. Electron cryotomography of Tula hantavirus suggests a unique assembly paradigm for enveloped viruses. J. Virol. 84, 4889\u20134897 (2010).","journal-title":"J. Virol."},{"key":"991_CR26","doi-asserted-by":"crossref","unstructured":"Engdahl, T. B. & Crowe, J. E., Jr Humoral immunity to hantavirus infection. mSphere 5, 10\u20131128 (2020).","DOI":"10.1128\/msphere.00482-20"},{"key":"991_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.671694","volume":"11","author":"H Sun","year":"2021","unstructured":"Sun, H. et al. Integrative analysis of HTNV glycoprotein derived MHC II epitopes by in silico prediction and experimental validation. Front. Cell. Infect. Microbiol. 11, 671694 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"991_CR28","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1128\/JVI.02279-06","volume":"81","author":"N Sen","year":"2007","unstructured":"Sen, N., Sen, A. & Mackow, E. R. Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J. Virol. 81, 4323\u20134330 (2007).","journal-title":"J. Virol."},{"key":"991_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.virusres.2013.12.034","volume":"187","author":"SS Ganaie","year":"2014","unstructured":"Ganaie, S. S. & Mir, M. A. The role of viral genomic RNA and nucleocapsid protein in the autophagic clearance of hantavirus glycoprotein Gn. Virus Res. 187, 72\u201376 (2014).","journal-title":"Virus Res."},{"key":"991_CR30","doi-asserted-by":"publisher","unstructured":"Sehgal, A. et al. Hemorrhagic fever with renal syndrome in Asia: history, pathogenesis, diagnosis, treatment, and prevention. Viruses 15, https:\/\/doi.org\/10.3390\/v15020561 (2023).","DOI":"10.3390\/v15020561"},{"key":"991_CR31","doi-asserted-by":"publisher","first-page":"1233433","DOI":"10.3389\/fmicb.2023.1233433","volume":"14","author":"S Afzal","year":"2023","unstructured":"Afzal, S. et al. Hantavirus: an overview and advancements in therapeutic approaches for infection. Front. Microbiol. 14, 1233433 (2023).","journal-title":"Front. Microbiol."},{"key":"991_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fcimb.2016.00185","volume":"6","author":"LF Cheng","year":"2016","unstructured":"Cheng, L. F. et al. Incorporation of GM-CSF or CD40L enhances the immunogenicity of hantaan virus-like particles. Front. Cell. Infect. Microbiol. 6, 185 (2016).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"991_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/1469-0691.12553","volume":"20","author":"JW Hooper","year":"2014","unstructured":"Hooper, J. W. et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin. Microbiol. Infect. 20, 110\u2013117 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"991_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2023.199149","volume":"334","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Investigation of a subunit protein vaccine for HFRS based on a consensus sequence between envelope glycoproteins of HTNV and SEOV. Virus Res. 334, 199149 (2023).","journal-title":"Virus Res."},{"key":"991_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"991_CR36","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong, Y., Lin, Y., Wei, T. & Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv. Mater. 35, e2303261 (2023).","journal-title":"Adv. Mater."},{"key":"991_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0264-410X(02)00574-1","volume":"21","author":"LA Babiuk","year":"2003","unstructured":"Babiuk, L. A., Pontarollo, R., Babiuk, S., Loehr, B. & van Drunen Littel-van den Hurk, S. Induction of immune responses by DNA vaccines in large animals. Vaccine 21, 649\u2013658 (2003).","journal-title":"Vaccine"},{"key":"991_CR38","doi-asserted-by":"crossref","unstructured":"Hooper, J. et al. A Phase 2a randomized, double-blind, dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Vaccines 8, 377 (2020).","DOI":"10.3390\/vaccines8030377"},{"key":"991_CR39","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse, M., Vrba, S. M., Kirk, N., Liang, Y. & Ly, H. Emerging concepts and technologies in vaccine development. Front. Immunol. 11, 583077 (2020).","journal-title":"Front. Immunol."},{"key":"991_CR40","doi-asserted-by":"publisher","first-page":"e2004452","DOI":"10.1002\/adma.202004452","volume":"32","author":"C Zeng","year":"2020","unstructured":"Zeng, C. et al. Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Adv. Mater. 32, e2004452 (2020).","journal-title":"Adv. Mater."},{"key":"991_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174\u20131185 (2019).","journal-title":"Nat. Biotechnol."},{"key":"991_CR42","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","volume":"18","author":"RL Ball","year":"2018","unstructured":"Ball, R. L., Hajj, K. A., Vizelman, J., Bajaj, P. & Whitehead, K. A. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett. 18, 3814\u20133822 (2018).","journal-title":"Nano Lett."},{"key":"991_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/infdis\/jit540","volume":"209","author":"TD Carroll","year":"2014","unstructured":"Carroll, T. D. et al. Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid\/DNA adjuvant. J. Infect. Dis. 209, 24\u201333 (2014).","journal-title":"J. Infect. Dis."},{"key":"991_CR44","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1016\/j.vaccine.2009.04.054","volume":"27","author":"M Lay","year":"2009","unstructured":"Lay, M. et al. Cationic lipid\/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27, 3811\u20133820 (2009).","journal-title":"Vaccine"},{"key":"991_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.antiviral.2011.04.006","volume":"90","author":"JD Morrey","year":"2011","unstructured":"Morrey, J. D., Motter, N. E., Chang, S. & Fairman, J. Breaking B and T cell tolerance using cationic lipid\u2013DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antivir. Res. 90, 227\u2013230 (2011).","journal-title":"Antivir. Res."},{"key":"991_CR46","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.actatropica.2013.07.021","volume":"128","author":"H Firouzmand","year":"2013","unstructured":"Firouzmand, H. et al. Induction of protection against leishmaniasis in susceptible BALB\/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop. 128, 528\u2013535 (2013).","journal-title":"Acta Trop."},{"key":"991_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 114, 100\u2013109 (2006).","journal-title":"J. Control Release"},{"key":"991_CR48","doi-asserted-by":"publisher","first-page":"1020134","DOI":"10.3389\/fimmu.2023.1020134","volume":"14","author":"A Pfeifle","year":"2023","unstructured":"Pfeifle, A. et al. DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice. Front. Immunol. 14, 1020134 (2023).","journal-title":"Front. Immunol."},{"key":"991_CR49","doi-asserted-by":"publisher","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","volume":"10","author":"W Ho","year":"2021","unstructured":"Ho, W. et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv. Healthc. Mater. 10, e2001812 (2021).","journal-title":"Adv. Healthc. Mater."},{"key":"991_CR50","doi-asserted-by":"publisher","first-page":"2281733","DOI":"10.1080\/21645515.2023.2281733","volume":"19","author":"VM Andrade","year":"2023","unstructured":"Andrade, V. M. et al. Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models. Hum. Vaccine Immunother. 19, 2281733 (2023).","journal-title":"Hum. Vaccine Immunother."},{"key":"991_CR51","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/14760584.2023.2282065","volume":"22","author":"A Cagigi","year":"2023","unstructured":"Cagigi, A. & Douradinha, B. Have mRNA vaccines sentenced DNA vaccines to death? Expert Rev. Vaccines 22, 1154\u20131167 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"991_CR52","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).","journal-title":"Front. Immunol."},{"key":"991_CR53","doi-asserted-by":"publisher","unstructured":"Liu, M. A. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines 7, https:\/\/doi.org\/10.3390\/vaccines7020037 (2019).","DOI":"10.3390\/vaccines7020037"},{"key":"991_CR54","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1099\/vir.0.045302-0","volume":"93","author":"G Yan","year":"2012","unstructured":"Yan, G. et al. Identification of a novel B-cell epitope of Hantaan virus glycoprotein recognized by neutralizing 3D8 monoclonal antibody. J. Gen. Virol. 93, 2595\u20132600 (2012).","journal-title":"J. Gen. Virol."},{"key":"991_CR55","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1128\/JVI.07204-11","volume":"86","author":"IT Hussein","year":"2012","unstructured":"Hussein, I. T. et al. Autophagic clearance of Sin Nombre hantavirus glycoprotein Gn promotes virus replication in cells. J. Virol. 86, 7520\u20137529 (2012).","journal-title":"J. Virol."},{"key":"991_CR56","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.vaccine.2015.05.007","volume":"33","author":"DB Jiang","year":"2015","unstructured":"Jiang, D. B. et al. Construction and evaluation of DNA vaccine encoding Hantavirus glycoprotein N-terminal fused with lysosome-associated membrane protein. Vaccine 33, 3367\u20133376 (2015).","journal-title":"Vaccine"},{"key":"991_CR57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.antiviral.2017.12.011","volume":"150","author":"DB Jiang","year":"2018","unstructured":"Jiang, D. B. et al. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy. Antivir. Res 150, 174\u2013182 (2018).","journal-title":"Antivir. Res"},{"key":"991_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2016.12.001","volume":"138","author":"DB Jiang","year":"2017","unstructured":"Jiang, D. B. et al. Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice. Antivir. Res. 138, 32\u201339 (2017).","journal-title":"Antivir. Res."},{"key":"991_CR59","doi-asserted-by":"publisher","first-page":"e0003803","DOI":"10.1371\/journal.pntd.0003803","volume":"9","author":"N Haese","year":"2015","unstructured":"Haese, N. et al. Antiviral biologic produced in DNA vaccine\/goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. PLoS Negl. Trop. Dis. 9, e0003803 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"991_CR60","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1080\/21645515.2017.1347740","volume":"13","author":"DAJ Mitchell","year":"2017","unstructured":"Mitchell, D. A. J. et al. Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice. Hum. Vaccine Immunother. 13, 2883\u20132893 (2017).","journal-title":"Hum. Vaccine Immunother."},{"key":"991_CR61","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.282.5388.476","volume":"282","author":"R Wang","year":"1998","unstructured":"Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476\u2013480 (1998).","journal-title":"Science"},{"key":"991_CR62","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1016\/j.vaccine.2012.04.007","volume":"30","author":"E Vardas","year":"2012","unstructured":"Vardas, E. et al. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(\u00ae)-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine 30, 4046\u20134054 (2012).","journal-title":"Vaccine"},{"key":"991_CR63","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","volume":"61","author":"L Chudley","year":"2012","unstructured":"Chudley, L. et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol. Immunother. 61, 2161\u20132170 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"991_CR64","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","volume":"385","author":"H Kibuuka","year":"2015","unstructured":"Kibuuka, H. et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385, 1545\u20131554 (2015).","journal-title":"Lancet"},{"key":"991_CR65","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"991_CR66","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"991_CR67","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"991_CR68","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"991_CR69","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","volume":"16","author":"LM Ickenstein","year":"2019","unstructured":"Ickenstein, L. M. & Garidel, P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin. Drug Deliv. 16, 1205\u20131226 (2019).","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00991-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00991-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00991-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T06:03:08Z","timestamp":1729663388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00991-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00991-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3933421\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}